Aerovate Therapeutics, Inc
https://www.aerovatetx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aerovate Therapeutics, Inc
Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives
Restructuring Edition: Financial market conditions are improving, but gains have not stopped some companies from cutting costs or shutting down. MEI may wind down if it does not identify another strategic alternative and Aslan has begun to liquidate, while others have cut jobs.
Aerovate Tanks On Trial Catastrophe
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
Keeping Up The Pressure In Pulmonary Arterial Hypertension
Merck & Co leads a market expected to exceed $10bn by 2028, but others are aiming to muscle in.
IPO Update: Booming Biopharma On Pace For Another Record Year
Only 25 more initial public offerings are needed for 2021 to beat 2020’s record-breaking 86 IPOs. However, the average return for this year’s offerings is just 1.1% as of 1 July versus 11% at the end of the first quarter.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice